18-methoxycoronaridine
18-Methoxycoronaridine, also known as zolunicant, is a derivative of ibogaine invented in 1996 by the research team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemists Upul K. Bandarage and Martin E. Kuehne from the University of Vermont. In animal studies it has proven to be effective at reducing self-administration of morphine, cocaine, methamphetamine, nicotine, and sucrose. It has also been shown to produce anorectic effects in obese rats, most likely due to the same actions on the reward system which underlie its anti-addictive effects against drug addiction. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2017 (NCT03084952)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)[C@H]13- Mol. weight
- 368.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia18-Methoxycoronaridine ↗
- ChEMBLCHEMBL607048 ↗
Also known as
- 18-mc compound
- 18-methoxycoronaridine
- 18-methoxycoronaridine
- 18-methoxycoronaridine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04292197 | Phase 1 | Apr 14, 2020 | Mind Medicine, Inc. |
| NCT03084952 | Phase 2 | Jun 1, 2017 | Infan Industria Quimica Farmaceutica Nacional, Oswaldo Cruz Foundation |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Infan Industria Quimica Farmaceutica Nacional | For profit | 1 | 1 | 1 | 2017 |
| Mind Medicine, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Oswaldo Cruz Foundation | Academic/Hospital | 1 | 0 | 1 | 2017 |